Cullinan Oncology
CGEM
174 hedge funds and large institutions have $931M invested in Cullinan Oncology in 2026 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 61 increasing their positions, 42 reducing their positions, and 17 closing their positions.
198% more call options, than puts
Call options by funds: $2.92M | Put options by funds: $978K
135% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 17
45% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 42
42% more capital invested
Capital invested by funds: $654M → $931M (+$277M)
14% more funds holding
Funds holding: 153 → 174 (+21)
1.36% more ownership
Funds ownership: 106.96% → 108.32% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$25.5M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$8.16M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.01M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$5.27M |
| 5 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$5.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
-$14.8M |
| 2 |
BOCH
Blue Owl Capital Holdings
New York
|
-$5.67M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.29M |
| 4 |
Renaissance Technologies
New York
|
-$3.95M |
| 5 |
Goldman Sachs
New York
|
-$3.42M |
CGEM Hedge Fund Activity: Q1 2026 in Review
174 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Cullinan Oncology (CGEM) for Q1 2026, worth a combined $931M — up 42% from $654M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new CGEM positions and 17 closed out — a net gain of 23 holders — while 61 added to existing stakes and 42 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $25.5M. The largest seller was Affinity Asset Advisors, cutting an estimated $14.8M.
- 174 institutional investors held Cullinan Oncology (CGEM) as of Q1 2026, up from 153 in Q4 2025.
- Funds reported $931M of Cullinan Oncology stock for Q1 2026, up 42% quarter-over-quarter.
- 40 funds opened new Cullinan Oncology positions in Q1 2026 and 17 closed out, a net change of +23 holders.
- The largest Cullinan Oncology buyer in Q1 2026 was T. Rowe Price Associates, an estimated $25.5M added.
- The largest Cullinan Oncology seller in Q1 2026 was Affinity Asset Advisors, an estimated $14.8M sold.
Based on aggregated 13F filings for Q1 2026.